DUBLIN–(BUSINESS WIRE)–The “Cancer
Immunotherapy Market By Type (Monoclonal Antibodies, Checkpoint
Inhibitors, Immunomodulators, Vaccines, Cell Therapy), Application
(Lung, Breast, Multiple Myeloma, Colorectal, Melanoma, Prostate), And
End User- Global Forecast To 2024” report has been added to ResearchAndMarkets.com’s
The global cancer immunotherapy market is expected to grow at a CAGR of
13.8% from 2018 to reach USD 152.83 billion by 2024.
The high growth of cancer immunotherapy market is attributed to factors
such as rising incidence of cancer globally, rising adoption of cancer
immunotherapies over other conventional cancer treatments owing to the
increased survival rate and less side effects with immunotherapy drugs,
increasing number of ongoing clinical trials with the help of rising
investments by major players in the market, and development of
bioinformatics tools that are enhancing the drug development process for
cancer immunotherapy market.
However, the high cost of the cancer immunotherapy treatment is
restricting the growth of this market to some extent. Apart from this,
growing R&D investments by major players in the market to develop cancer
immunotherapies and high growth prospects in the developing countries
such as China and India provides significant opportunity in this market.
Monoclonal antibodies dominated the global cancer immunotherapy market,
mainly due to their high adoption for cancer treatment, rising number of
US FDA approvals, and better five-year survival rates as compared to
other cancer treatment options available in the market.
Cancer immunotherapy market for lung cancer application commanded the
largest share, mainly attributed to increasing incidence of lung cancer,
the significant benefit of cancer immunotherapy for lung cancer compared
with other treatment options, and rising adoption of immunotherapies in
lung cancer owing to the higher survival rate.
- Rising Cancer Incidence
- Growing Adoption of Immunotherapy over other Treatment Options
- Increasing Number of Technological Collaborations and Mergers
- Development of Bioinformatics Tools Enhancing Drug Development Process
- High Cost of Treatment
- Growing R&D Expenditure
- High Growth Prospects in Emerging Economies
- Limited Funds with Small and Mid-Sized Organizations to Initiate the
- Complexities of Tumor
Key Topics Covered
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Industry Insights
6. Cancer Immunotherapy Market, by Type
7. Cancer Immunotherapy Market, by Application
8. Cancer Immunotherapy Market, by End-User
9. Cancer Immunotherapy Market, by Region
10. Competitive Landscape
11. Company Profiles
- Amgen Inc.
- Bristol-Myers Squibb
- Celgene Corporation
- Dendreon Pharmaceuticals
- Eli Lilly and Company
- F. Hoffmann-La Roche
- Gilead Sciences Inc.
- Janssen Global Services LLC
- Merck & Co. Inc.
- Pfizer Inc.
For more information about this report visit https://www.researchandmarkets.com/research/ssxbrz/the_global_market?w=4
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Disorders Drugs, Biopharmaceuticals